Assessment of Sacsin Turnover in Patients With ARSACS
Open Access
- 7 December 2021
- journal article
- research article
- Published by Wolters Kluwer Health in Neurology
- Vol. 97 (23) , e2315-e2327
Abstract
Background and Objectives Autosomal recessive spastic ataxia of Charlevoix-Saguenay (ARSACS) is caused by variations in SACS gene encoding sacsin, a huge multimodular protein of unknown function. More than 200 SACS variations have been described worldwide to date. Because ARSACS presents phenotypic variability, previous empirical studies attempted to correlate the nature and position of SACS variations with the age at onset or with disease severity, although not considering the effect of the various variations on protein stability. In this work, we studied genotype-phenotype correlation in ARSACS at a functional level. Methods We analyzed a large set of skin fibroblasts derived from patients with ARSACS, including both new and already published cases, carrying variations of different types affecting diverse domains of the protein. Results We found that sacsin is almost absent in patients with ARSACS, regardless of the nature of the variation. As expected, we did not detect sacsin in patients with truncating variations. We found it strikingly reduced or absent also in compound heterozygotes carrying diverse missense variations. In this case, we excluded SACS mRNA decay, defective translation, or faster posttranslational degradation as possible causes of protein reduction. Conversely, our results demonstrate that nascent mutant sacsin protein undergoes cotranslational ubiquitination and degradation. Discussion Our results provide a mechanistic explanation for the lack of genotype-phenotype correlation in ARSACS. We also propose a new and unambiguous criterion for ARSACS diagnosis that is based on the evaluation of sacsin level. Last, we identified preemptive degradation of a mutant protein as a novel cause of a human disease.Keywords
This publication has 42 references indexed in Scilit:
- Comparative Analysis and Functional Mapping of SACS Mutations Reveal Novel Insights into Sacsin Repeated ArchitectureHuman Mutation, 2013
- Autosomal recessive spastic ataxia of Charlevoix Saguenay (ARSACS): expanding the genetic, clinical and imaging spectrumOrphanet Journal of Rare Diseases, 2013
- Structural Basis of Defects in the Sacsin HEPN Domain Responsible for Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS)Journal of Biological Chemistry, 2011
- The Sacsin Repeating Region (SRR): A Novel Hsp90-Related Supra-Domain Associated with NeurodegenerationJournal of Molecular Biology, 2010
- JNK inhibition arrests cotranslational degradationBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2010
- The Angelman Syndrome Protein Ube3A Regulates Synapse Development by Ubiquitinating ArcCell, 2010
- The ataxia protein sacsin is a functional co-chaperone that protects against polyglutamine-expanded ataxin-1Human Molecular Genetics, 2009
- An inherited large-scale rearrangement in SACS associated with spastic ataxia and hearing lossneurogenetics, 2008
- ARSACS, a spastic ataxia common in northeastern Québec, is caused by mutations in a new gene encoding an 11.5-kb ORFNature Genetics, 2000
- Regulated Co-translational Ubiquitination of Apolipoprotein B100Journal of Biological Chemistry, 1998